With $500M-plus, a buyout and two new billion-dollar pacts, upstart Vir is ready to roll on infectious diseases
George Scangos has been busy since leaving Biogen’s helm and jumping to the startup Vir Biotechnology in San Francisco. Now it’s time for the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
